Naureen Starling

Has grant

Reader

Institute of Cancer Research

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

ORCID

Google Scholar

About

Naureen Starling is a Reader at The Institute of Cancer Research in the United Kingdom. Her research focuses on colorectal and gastrointestinal cancers, particularly in the areas of molecular profiling, mismatch repair screening, and precision medicine. Recent publications include studies on the genetic and immune landscape of colorectal cancer and the efficacy of targeted therapies in gastric cancer.

Recent Grants

Grant: Open

Novel blood test to personalise Early Stage Colorectal Cancer treatment

Open Date: 2020-01-01

Close Date: 2027-12-31

Grant: Close

Inhibitors of Lysyl Oxidase for the Prevention and Treatment of Invasive and Metastatic Cancer The enzyme lysyl oxidase (LOX) regulates cross-linking of structural proteins in the extracellular matrix

Open Date: 2014-09-01

Close Date: 2018-08-31

Grant: Close

Inhibitors of Lysyl Oxidase for the Prevention and Treatment of Invasive and Metastatic Cancer

Open Date: 2014-09-01

Close Date: 2017-08-31

Grant: Close

SBRI Healthcare Cancer Programme: SBRIC01P3008 - Liquid Biopsies for Faster Diagnosis of Pancreatic and Biliary Tract Cancers

Open Date:

Close Date:

Naureen Starling

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (19)

Clinical and Molecular Profiling of Colorectal Cancer: A Comprehensive Cohort Study of BRAF-Mutated Cases from a Tertiary Centre

Genetic and immune landscape evolution in MMR-deficient colorectal cancer

Targeted Therapies and Developing Precision Medicine in Gastric Cancer

Mismatch Repair Screening of Gastrointestinal Cancers: The Impact on Lynch Syndrome Detection and Immunotherapy

Targeted Therapies and Developing Precision Medicine in Gastric Cancer

Efficacy and safety of dostarlimab in UK-specific patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) or DNA polymerase epsilon, catalytic subunit (POLε)-mutated solid tumours in the GARNET study

PD1 and LAG3 inhibition as second plus line treatment after EGFR antibody-containing therapy in RAS/BRAF wildtype, MMRp metastatic colorectal cancer

Circulating tumor DNA for recurrence prediction and efficacy analysis in the ICONIC trial of peri-operative FLOT and avelumab (PD-L1) in localized esophago-gastric adenocarcinoma

Clonal mutation burden and evolutionary dynamics analysis in metastatic gastro-esophageal adenocarcinoma (GEA) by error corrected whole-exome circulating tumor DNA sequencing

The Role of ctDNA in Gastric Cancer

Neoadjuvant and Adjuvant Therapy Approaches to Gastric Cancer

Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study

Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors

Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study

Mismatch Repair Screening of Gastrointestinal Cancers: The Impact on Lynch Syndrome Detection and Immunotherapy.

Beyond Teenage and Young Adult Cancer Care: Care Experiences of Patients Aged 25-39 Years Old in the UK National Health Service.

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.

The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing.

Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes.

Collaborators (4)

Lajos Pusztai

Marco Gerlinger

Mark Openshaw

Ian Chau

How do I reach out?

Meet Kite AI